A citation-based method for searching scientific literature

Hong Jun Kim, Jae Joon Han, Chi Hoon Maeng, Sun Kyung Baek. Int J Gen Med 2020
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Gerald S Falchook, Michael Millward, David Hong, Aung Naing, Sarina Piha-Paul, Steven G Waguespack, Maria E Cabanillas, Steven I Sherman, Bo Ma, Martin Curtis,[...]. Thyroid 2015
126
100

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
192
100

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
673
100


Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Maria E Cabanillas, Mabel Ryder, Camilo Jimenez. Endocr Rev 2019
101
100

The RET oncogene in papillary thyroid carcinoma.
Jason D Prescott, Martha A Zeiger. Cancer 2015
50
100

Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Peng Hou, Dingxie Liu, Yuan Shan, Shuiying Hu, Kimberley Studeman, Stephen Condouris, Yangang Wang, Ariel Trink, Adel K El-Naggar, Giovanni Tallini,[...]. Clin Cancer Res 2007
287
100

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
371
100

The Role of ATP-Binding Cassette Transporters in the Chemoresistance of Anaplastic Thyroid Cancer: A Systematic Review.
Elnaz Abbasifarid, Sayed Mahmoud Sajjadi-Jazi, Maryam Beheshtian, Hilda Samimi, Bagher Larijani, Vahid Haghpanah. Endocrinology 2019
17
100

Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.
M Santoro, N A Dathan, M T Berlingieri, I Bongarzone, C Paulin, M Grieco, M A Pierotti, G Vecchio, A Fusco. Oncogene 1994
305
100

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Eric J Sherman, Lara A Dunn, Alan L Ho, Shrujal S Baxi, Ronald A Ghossein, Matthew G Fury, Sofia Haque, Cami S Sima, Grace Cullen, James A Fagin,[...]. Cancer 2017
43
100

Drug resistance in cancer: an overview.
Genevieve Housman, Shannon Byler, Sarah Heerboth, Karolina Lapinska, Mckenna Longacre, Nicole Snyder, Sibaji Sarkar. Cancers (Basel) 2014
100

Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma.
Weilin Pu, Xiao Shi, Pengcheng Yu, Meiying Zhang, Zhiyan Liu, Licheng Tan, Peizhen Han, Yu Wang, Dongmei Ji, Hualei Gan,[...]. Nat Commun 2021
9
100

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Jierui Liu, Yanqing Liu, Yansong Lin, Jun Liang. Endocrinol Metab (Seoul) 2019
32
100

Lenvatinib: Role in thyroid cancer and other solid tumors.
Maria E Cabanillas, Mouhammed Amir Habra. Cancer Treat Rev 2016
100
100

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
283
100

Acquired Resistance Is Oncogene and Drug Agnostic.
Robert C Doebele. Cancer Cell 2019
15
100

Survival and death causes in differentiated thyroid carcinoma.
Carmen F A Eustatia-Rutten, Eleonora P M Corssmit, Nienke R Biermasz, Alberto M Pereira, Johannes A Romijn, Johannes W Smit. J Clin Endocrinol Metab 2006
196
100

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
100

Cell signaling by receptor tyrosine kinases.
Mark A Lemmon, Joseph Schlessinger. Cell 2010
100

Medullary thyroid carcinoma.
Sophie Leboulleux, Eric Baudin, Jean-Paul Travagli, Martin Schlumberger. Clin Endocrinol (Oxf) 2004
222
100

Potential of epigenetic events in human thyroid cancer.
Abdelkareem A Ahmed, Mohammed Elmujtba Adam Essa. Cancer Genet 2019
8
100

Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Helton Estrela Ramos, Fabio Hecht, Amandine Berdelou, Isabelle Borget, Sophie Leboulleux, Eric Baudin, Martin Schlumberger. Endocrine 2021
10
100

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.
Loredana Lorusso, Virginia Cappagli, Laura Valerio, Carlotta Giani, David Viola, Luciana Puleo, Carla Gambale, Elisa Minaldi, Maria Cristina Campopiano, Antonio Matrone,[...]. Int J Mol Sci 2021
15
100

Dose-dependent inhibition of thyroid differentiation by RAS oncogenes.
Gabriella De Vita, Lisa Bauer, Vania M Correa da Costa, Mario De Felice, Maria Giuseppina Baratta, Marta De Menna, Roberto Di Lauro. Mol Endocrinol 2005
52
100

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
R M Hofstra, R M Landsvater, I Ceccherini, R P Stulp, T Stelwagen, Y Luo, B Pasini, J W Höppener, H K van Amstel, G Romeo. Nature 1994
946
100

Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.
Stacey A Dacosta Byfield, Oluwakayode Adejoro, Ronda Copher, Debanjana Chatterjee, Prashant R Joshi, Francis P Worden. Adv Ther 2019
9
100

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Edna T Kimura, Marina N Nikiforova, Zhaowen Zhu, Jeffrey A Knauf, Yuri E Nikiforov, James A Fagin. Cancer Res 2003
100

Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Laura Valerio, Valeria Bottici, Antonio Matrone, Paolo Piaggi, David Viola, Virginia Cappagli, Laura Agate, Eleonora Molinaro, Raffaele Ciampi, Alessia Tacito,[...]. Endocr Relat Cancer 2020
10
100

REToma: a cancer subtype with a shared driver oncogene.
Takashi Kohno, Junya Tabata, Takashi Nakaoku. Carcinogenesis 2020
21
100

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
560
100

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
865
100

The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.
Amandeep Singh, Jeehoon Ham, Joseph William Po, Navin Niles, Tara Roberts, Cheok Soon Lee. Cells 2021
6
100

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
213
100

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
90
100

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei. Front Endocrinol (Lausanne) 2022
3
100

Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
617
100

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Vivek Subbiah, Mimi I Hu, Lori J Wirth, Martin Schuler, Aaron S Mansfield, Giuseppe Curigliano, Marcia S Brose, Viola W Zhu, Sophie Leboulleux, Daniel W Bowles,[...]. Lancet Diabetes Endocrinol 2021
65
100

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
182
100

Multimodality treatment in anaplastic giant cell thyroid carcinoma.
E Tallroth, G Wallin, G Lundell, T Löwhagen, J Einhorn. Cancer 1987
63
100

Kinase inhibitors for advanced medullary thyroid carcinoma.
Martin Schlumberger, Marie-Hélène Massicotte, Camila L Nascimento, Cécile Chougnet, Eric Baudin, Sophie Leboulleux. Clinics (Sao Paulo) 2012
14
100

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
Colin J Mooney, Govardhanan Nagaiah, Pingfu Fu, Jay K Wasman, Matthew M Cooney, Panos S Savvides, Joseph A Bokar, Afshin Dowlati, Ding Wang, Sanjiv S Agarwala,[...]. Thyroid 2009
135
100

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
60
100

Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
Carlotta Giani, Laura Valerio, Alberto Bongiovanni, Cosimo Durante, Giorgio Grani, Toni Ibrahim, Stefano Mariotti, Michela Massa, Fabiana Pani, Gabriella Pellegriti,[...]. Thyroid 2021
18
100

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
974
100

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.
Vatche Tchekmedyian, Lara Dunn, Eric Sherman, Shrujal S Baxi, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra,[...]. Thyroid 2022
5
100

Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.
F Pacini, F Basolo, R Bellantone, G Boni, M A Cannizzaro, M De Palma, C Durante, R Elisei, G Fadda, A Frasoldati,[...]. J Endocrinol Invest 2018
97
100

A perspective view of sodium iodide symporter research and its clinical implications.
Garcilaso Riesco-Eizaguirre, Pilar Santisteban. Eur J Endocrinol 2006
133
100

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
Alan L Ho, Marek Dedecjus, Lori J Wirth, R Michael Tuttle, William B Inabnet, Jan Tennvall, Fernanda Vaisman, Lars Bastholt, Andrew G Gianoukakis, Patrice Rodien,[...]. J Clin Oncol 2022
4
100

Expression of epithelial-mesenchymal transition regulators TWIST, SLUG and SNAIL in follicular thyroid tumours may relate to widely invasive, poorly differentiated and distant metastasis.
Jianghua Wu, Yanhui Zhang, Runfen Cheng, Wenchen Gong, TingTing Ding, Qiongli Zhai, Yong Wang, Bin Meng, Baocun Sun. Histopathology 2019
19
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.